Immunotherapy drug DOUBLES survival in lung cancer patients

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news